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Invasive nonfunctional pituitary adenomas (NFPAs) are difficult to completely resect and often develop tumor recurrence after 
initial surgery. Currently, no medications are clinically effective in the control of NFPA. Although radiation therapy and radi-
osurgery are useful to prevent tumor regrowth, they are frequently withheld because of severe complications. Boron neutron 
capture therapy (BNCT) is a binary radiotherapy that selectively and maximally damages tumor cells without harming the sur-
rounding normal tissue. Folate receptor (FR)-targeted boron-10 containing carbon nanoparticles is a novel boron delivery agent 
that can be selectively taken up by FR-expressing cells via FR-mediated endocytosis. In this study, FR-targeted boron-10 con-
taining carbon nanoparticles were selectively taken up by NFPAs cells expressing FR but not other types of non-FR expressing 
pituitary adenomas. After incubation with boron-10 containing carbon nanoparticles and following irradiation with thermal 
neutrons, the cell viability of NFPAs was significantly decreased, while apoptotic cells were simultaneously increased. However, 
cells administered the same dose of FR-targeted boron-10 containing carbon nanoparticles without neutron irradiation or received 
the same neutron irradiation alone did not show significant decrease in cell viability or increase in apoptotic cells. The expression 
of Bcl-2 was down-regulated and the expression of Bax was up-regulated in NFPAs after treatment with FR-mediated BNCT. In 
conclusion, FR-targeted boron-10 containing carbon nanoparticles may be an ideal delivery system of boron to NFPAs cells 
for BNCT. Furthermore, our study also provides a novel insight into therapeutic strategies for invasive NFPA refractory to 
conventional therapy, while exploring these new applications of BNCT for tumors, especially benign tumors.  
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Pituitary adenomas (PAs) account for approximately 15% 
of intracranial tumors and are the second most common 
intracranial neoplasm after gliomas [1]. Nonfunctional pitu-
itary adenomas (NFPAs) are the most common form of PA 
and account for approximately 30% of PAs [2]. Because of 
the lack of clinical symptoms, NFPAs are often diagnosed 
with variable delay at which point patients suffer from 
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compression symptoms (hypopituitarism, headache and 
visual field defects). Surgery is the first-line treatment for 
NFPAs, but approximately 40% of them have invasion of 
bone, dura, and/or adjacent structures. These invasive 
NFPAs are difficult to resect completely and the patients 
often develop tumor recurrence quickly after initial surgery 
[3]. Thus, further pharmacotherapy is required to control 
symptoms. However, to date no medical treatment has 
proven to be clinically effective in the control of NFPAs. 
Although conventional radiotherapy and stereotactic radio-
surgery are useful third-line strategies to prevent tumor re-
growth, they are associated with severe complications such 
as secondary brain neoplasm, optic neuropathy, cerebro-
vascular accidents, and hypopituitarism, which can serious-
ly impair patients’ quality of life or lead to death [46]. 
Therefore, there is an urgent need to identify new therapeu-
tic strategies for invasive NFPAs refractory to standard 
therapy including repeated surgeries, radiotherapy and al-
ternative medical therapies. 
Boron neutron capture therapy (BNCT) is a binary form 
of radiation therapy that selectively and maximally damages 
tumor cells without harming the surrounding normal tissue 
[7]. BNCT is based on nuclear reactions that occur when 
boron-10 atoms are irradiated by low-energy thermal neu-
trons to yield alpha particles and recoiling lithium-7 nuclei, 
which have high lineal energy transfer (LET) values and 
significant biological effects [8]. The path-lengths of alpha 
particles and recoiling lithium-7 nuclei are 9 and 5 m, re-
spectively, which is approximately the diameter of a single 
tumor cell. Therefore, the lethality of these nuclei is limited 
to boron-containing tumor cells, while normal cells survive 
without exposure to alpha particles and recoiling lithium-7 
nuclei [9]. Two fundamental criteria must be met for BNCT: 
(i) the drug must deliver boron to tumor tissues in concen-
trations greater than 20–30 g g1 tissue at the time of irra-
diation; (ii) there must be an appropriate source of thermal 
neutrons for BNCT [10]. 
The major challenge in the development of BNCT is to 
develop a safe and selective boron delivery agent. Success-
ful boron agents for BNCT are required to accumulate high 
boron concentrations in tumor cells with high selectivity 
and with minimal normal tissue toxicity. Currently, sodium 
borocaptate (BSH) and boronophenylalanine (BPA) are 
used clinically for patients [11]. However, BSH and BPA 
have failed to satisfy clinical requirements completely be-
cause of their limitations, such as insufficient selectivity, 
toxicity to the human body, low retention time in tumors 
and low chemical stability [12].  
Folate receptor (FR) is an important therapeutic target for 
tumor treatment. Folic acid (folate) can bind to FR with 
high affinity and transport drugs into cells via FR-mediated 
endocytosis [13]. Previously, FR-targeted boron-10 con-
taining carbon nanoparticles could be selectively taken up 
by highly FR-expressing HeLa cells and effectively kill the 
cells upon neutron irradiation [14]. Folate receptor alpha 
(FR) was shown to be uniquely overexpressed in NFPAs 
but not in functional pituitary adenomas (PFAs) or normal 
pituitary glands [15]. Moreover, we previously showed that 
expression of FR in NFPAs correlated positively with tu-
mor invasiveness and proliferation [16]. These findings 
raise the possibility that FR-targeted boron-10 containing 
carbon nanoparticles may be selectively taken up by NFPA 
cells for BNCT. In the present study, we sought to expand 
the application of BNCT for the treatment of NFPAs and 
determine whether FR-targeted boron-10-containing carbon 
nanoparticles could be used for the delivery of boron-10 to 
NFPA cells for BNCT. 
1  Materials and methods  
1.1  Chemicals and reagents 
FR-targeted boron-10-containing carbon nanoparticles were 
synthesized by Professor Hwang Kuo Chu (Department of 
Chemistry, Tsing Hua University, Hsinchu, Taiwan, China) 
[14]. Folate free RPMI 1640 medium was bought from 
Invitrogen (Beijing, China). Free folate was purchased from 
Sigma-Aldrich (Shanghai, China). The cell counting kit 
(CCK)-8 was supplied by Dojindo Laboratories (Kumamoto, 
Japan). Annexin V-FITC apoptosis assay kit was supplied 
by Biosea Biotechnology. The primary antibody for Bax 
was obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), and primary antibody for Bcl-2 was provided by 
Cell Signaling Technology (Danvers, MA, USA). Mouse 
anti-FR antibody (LS-C23683) was obtained from Lifespan 
BioSciences (Seattle, WA, USA), and the Cy3 affinipure 
goat anti-mouse IgG secondary antibody (E031610-01) was 
bought from EarthOx (San Francisco, CA, USA). 
1.2  Neutron resources device 
The source of neutrons was an in-hospital neutron irradiator 
mark 1 reactor (IHNI-1) (Beijing, China), designed by a 
member of the Chinese Academy of Engineering, Zhou 
YongMao and his colleagues [17]. IHNI-1 is exclusively 
used for boron neutron capture therapy (BNCT) based on a 
miniature neutron source reactor. The maximum of thermal 
neutron flux of IHNI-1 for irradiation is up to 1.8×109     
n cm2 s1. IHNI-1 is very safe and convenient for both the 
patients and operators.    
1.3  Primary cell culture  
Nineteen specimens of PAs (mean maximal diameter 32.3±    
9.4 mm) were obtained from surgical patients, who were 
hospitalized in the Peking Union Medical College Hospital 
(PUMCH) between September and November, 2011. All 
procedures related to tumor tissue handling were approved 
by the Research Ethics Committee of Peking Union Medical 
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College. Informed consent was obtained from every patient 
before the in vitro study.  
Specimens were collected from patients with 10 NFPAs, 
3 prolactin (PRL)-secreting PAs, 3 growth hormone (GH)-     
secreting PAs and 3 adrenocorticotropic hormone (ACTH)-      
producing PAs who underwent surgery. To culture primary 
PA tumor cells, tumor tissues were minced with scissors 
and digested in Accutase™ (Invitrogen) containing 1 mg of 
DNAse at 37°C for 1 h. After digestion, cells were sus-
pended, passed through a 40 m cell strainer and cultured in 
folate-free RPMI 1640 media (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS), penicillin (100 U mL1), 
streptomycin (100 g mL1), B-27®Supplement, N-2®Supple- 
ment, bFGF (20 ng mL1; Peprotech, Suzhou) and EGF (20 
ng mL1; Peprotech, Suzhou).  
1.4  Immunofluorescence analysis of FR expression  
The expression of FR on the membrane of primary culture 
PAs cells was determined by fluorescence immunocyto-
chemistry using confocal microscopy. Nineteen PA cells 
and positive control HeLa cells were planted into 
glass-bottomed dishes (Nest Biotechnology Corporation, 
Shanghai) coated with BD Matrigel™ Basement Membrane 
Matrix in folate-free RPMI 1640. After 48-h incubation (in 
an incubator with 80% humidity and O2/CO2 at 5%) the 
cells were fixed in 4% paraformaldehyde for 30 min, and 
permeabilized with 0.5% Triton X-100 for 5 min. After in-
cubation with blocking medium (PBS containing 10% nor-
mal horse serum and 2% BSA) for 30 min, cells were incu-
bated with FR primary antibody (LS-C23683, Lifespan 
BioSciences) overnight at 4°C. After three washes with PBS 
(5 min each), the cells were incubated with the Cy3 affini-
pure goat anti-mouse IgG (E031610-01, EarthOx) at room 
temperature for 2 h. Following three washes with PBS, the 
cell nuclei were stained with 4′6-diamidino-2-phenylindole 
(DAPI) for 30 min. After three washes with PBS (5 min 
each), the cells were covered with fluorescence mounting 
medium. Finally, the cells were visualized under a confocal 
scanning laser microscope (Zeiss 510; Zeiss, Heidelberg, 
Germany) and image analysis was performed using the 
standard system operating software provided with the Zeiss 
510 microscope. 
1.5  Uptake of FR-targeted Boron-10 containing carbon 
nanoparticles by pituitary adenoma cells 
Nineteen cases (10 NFPA with 8 cases overexpressing FR, 
3 PRL, 3 GH and 3 ACTH cases) of primary culture PA 
cells were cultured on glass-bottomed dishes coated with 
100 L BD Matrigel™ Basement Membrane Matrix in  
folate-free RPMI 1640 for 24 h. FR-targeted boron-10 con-
taining carbon nanoparticles were added to folate-free 
RPMI 1640 and incubated for 24 h at 37°C. Free folate   
(1 mmol L1) was added to the incubation media of the FR 
blocking group to determine the role of FR binding. The 
cells were washed three times with cold PBS to remove 
unbound FR-targeted boron-10 containing carbon nanopar-
ticles after incubation. Then the cell nuclei were stained 
with DAPI for 30 min. The cells were examined using a 
confocal scanning laser microscope.  
1.6  Cytotoxicity measurements of FR-targeted boron- 
10 containing carbon nanoparticles without neutron 
irradiation 
To measure the cytotoxicity of FR-targeted boron-10 con-
taining carbon nanoparticles, primary culture NFPA cells 
and GH-secreting PA cells were diluted with folate-free 
RPMI 1640 medium and seeded in 96-well plates at 1×104 
cells/well. Then the plate was incubated at 37°C for 24 h in 
an incubator. Then 20 L of PBS buffer solution containing 
different amounts of FR-targeted boron-10 containing car-
bon nanoparticles (ranging from 0.1 to 100 g mL1) were 
added to the wells, whereas 20 L of PBS buffer solution 
only was added to the control group. Then, the plates were 
incubated for another 24 h at 37°C in an incubator. CCK-8 
(10 L) was added to each well followed by incubation at 
37°C for 3 h. Finally, the absorbance was measured at a 
wavelength of 450–630 nm using a Victor-2 plate reader 
(Perkin Elmer, Waltham, MA, USA). Each experiment was 
performed three times. Cell viability was calculated as a 
percentage of the control. Data are the mean±SD from a 
single experiment performed with three duplicates.  
1.7  Intracellular boron concentration measurement  
To measure the boron concentration in PA cells accurately, 
the primary culture of NFPA cells and GH-secreting PA 
cells was incubated with 0.1 g mL1 FR-targeted boron-10 
containing carbon nanoparticles in folate-free RPMI 1640 
medium. The cells were collected at 2, 4, 8, 16 and 24 h 
after the addition of FR-targeted boron-10 containing car-
bon nanoparticles. The free FR-targeted boron-10 contain-
ing carbon nanoparticles in the medium were removed by 
centrifugation at 1000×g for 5 min and re-suspended in PBS. 
This procedure was repeated three times. The cells were 
collected and the boron concentration was determined by 
inductively coupled plasma-atomic emission spectrum 
(ICP-AES) according to a previously described method 
[18].  
1.8  Thermal neutron irradiation experiments  
The primary culture NFPA cells were planted in the center 
of 16 wells of a 96-well plate at a density of 1×104 cells/     
well, following an addition of 20 L of a PBS buffer solu-
tion containing 0.05, 0.1 or 0.2 g of FR-targeted boron-10 
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containing carbon nanoparticles to the treatment groups, and 
20 L of PBS only to the control group. After 24-h incuba-
tion the free FR-targeted boron-10 containing carbon nano-
particles were removed from the medium by centrifugation 
and wash with PBS for three times. Then the cells were re-
turned to a 96-well plate and irradiated by a thermal neutron 
beam from the nuclear reactor. The control for each group 
received the same neutron dose but without incubation with 
carbon nanoparticles. After irradiation at a neutron flux of 
1.8×109 n cm2 s1 for 10 min, the 96-well plates were fur-
ther incubated at 37°C for 24 and 48 h to determine cell 
viability using CCK-8. 
1.9  Annexin V/PI analysis  
At 48 h after NFPA cell irradiation with thermal neutrons, 
the Annexin V/PI assays were performed according to the 
manufacturer’s protocol (Biosea, China). Briefly, the NFPA 
cells were washed twice with PBS and resuspended with 
200 L binding buffer. 10 L of Annexin-V-FITC was 
added to the cells, followed by 30 min incubation at room 
temperature in the dark. After incubation, cells were coun-
terstained with 5 L PI (Sigma). The percentage of apop-
totic cells was determined using a FACS flow cytometer. 
Each experiment was performed three times. Data are the 
mean±SD from a single experiment with three duplicates.  
1.10  Western blotting  
To investigate the mechanisms involved in BNCT-induced 
cell death of NFPA cells, the expressions of Bax and Bcl-2 
were performed at 48 h after irradiation with thermal neu-
trons. Briefly, cell lysates were separated on a 10% poly-
acrylamide gel, electrophoretically transferred onto a PVDF 
membrane (PALL Corp., East Hills, NY, USA) and probed 
by standard techniques with primary antibodies raised 
against Bax and Bcl-2. All antibodies were used at a 1:1000 
dilution. HRP-conjugated goat anti-rabbit IgG (Cell Signal-
ing Technology) were used as secondary antibodies for rab-
bit anti-Bax (Santa Cruz Biotechnology) and rabbit anti-     
Bcl-2 (Cell Signaling Technology) primary antibodies. 
Horse anti-human IgG (Cell Signaling Technology) was 
used as a secondary antibody for the human anti-β-actin 
primary antibody (Santa Cruz Biotechnology).  
1.11  Statistical analysis 
The data were expressed as the mean±SD, with P<0.05 be-
ing considered statistically significant. The differences 
among groups were tested by one-way ANOVA, followed 
by Dunnett’s multiple range test. The differences between 
two groups were evaluated by the unpaired Student’s t-test. 
All statistical analyses were performed using SPSS.17.0 
statistical software.  
2  Results 
2.1  The expression of FR in PAs  
Before exploring whether FR-targeted boron-10 containing 
carbon nanoparticles could be taken up by NFPA cells for 
BNCT, the expression and location of FR in 19 cases of 
PA was analyzed by immunofluorescence. As shown in 
Figure 1, NFPA cells exhibited strong membrane staining 
for FR, similar to the positive control HeLa cells. In con-
trast, no membrane staining was observed in the FPAs. 
However, not all NFPA cells showed positive staining of 
membrane FR. In the present study, 8 of 10 NFPAs 
showed significant positive staining of FR, consistent with 
our previous study [16]. 
2.2  Uptake of FR-targeted boron-10 containing car-
bon nanoparticles by PA cells 
The uptake of FR-targeted boron-10 containing carbon na-
noparticles by PA cells was analyzed by fluorescence mi-
croscopy. Carbon nanoparticles were surface modified with 
folate moieties, which can induce green fluorescence under 
a FITC filter. As shown in Figure 2, FR-targeted boron-10 
containing carbon nanoparticles were more efficiently taken 
up by NFPA cells expressing FR compared to FPAs not 
expressing FR. FR-mediated uptake could be blocked by  
1 mmol L1 free folic acid. Taken together, our data show 
that FR-targeted boron-10 containing carbon nanoparticles 
could effectively be taken up by NFPA cells through FR-    
mediated endocytosis. 
2.3  Cytotoxicity of FR-targeted boron-10 containing 
carbon nanoparticles  
To investigate the cytotoxicity of FR-targeted boron-10 
containing carbon nanoparticles, we performed CCK-8 as-
say of PA cells after incubation with various concentrations 
of FR-targeted boron-10 containing carbon nanoparticles. 
FR-targeted boron-10 containing carbon nanoparticles re-
duced the viability of NFPAs in a concentration-dependent 
manner after 24 h incubation (Figure 3A). Although viabil-
ity of GH-secreting adenoma cells also was reduced in a 
concentration dependent manner, the cell viability was 
much higher than for NFPAs after incubation with the same 
concentration of FR-targeted drugs. The above results were 
similar to the positive control (HeLa cell line) and negative 
control (non-FR-expressing mouse gonadotroph adenoma 
cell line, T3-1), respectively (Figure 3B). 
2.4  Time-course of boron concentration in PAs 
To investigate the time-course of boron accumulation, bo-
ron concentration in PAs was evaluated by ICP-AES for  
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Figure 1  Expression and location of FR in PAs and HeLa cells. Strong expression of FR was detected on the cellular membrane of NFPAs and positive 
control HeLa cells. FR was not detected on the cellular membrane of GH adenoma cells, PRL adenoma cells and ACTH adenoma cells.  
each post-administration time point. Boron accumulation in 
the NFPA tumor cells increased in a time dependent manner, 
and the boron concentration reached a maximum value 
(246.8 g g1) after 24-h incubation with FR-targeted bo-
ron-10 containing carbon nanoparticles (Figure 4A). In con-
trast, GH-secreting PAs did not show significant increases 
in boron concentration in a time dependent manner, and the 
boron concentrations at the same time points were much 
lower than for NFPA tumor cells. Similar results were ob-
served in the positive control (HeLa cell line) and the nega-
tive control (T3-1 cell line) (Figure 4B). The boron con-
centration in HeLa cells was much higher than in T3-1  
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Figure 2  Uptake of FR-targeted boron-10 containing carbon nanoparticles by PAs. PAs were incubated with FR-targeted boron-10 containing carbon 
nanoparticles at a dose of 0.1 mg mL1 or FR-targeted boron-10 containing carbon nanoparticles plus 1 mmol L1 free folic acid for 24 h. Green fluorescence 
represents the folate moieties on FR-targeted boron-10 containing carbon nanoparticles under a FITC filter. FR-targeted boron-10 containing carbon nano-
particles were taken up by NFPAs with FR expression. The FR-targeted boron-10 containing carbon nanoparticles were not taken up by GH adenoma cells, 
PRL adenoma cells or ACTH adenoma cells. The cellular uptake of FR-targeted boron-10 containing carbon nanoparticles could be blocked by addition of 
1 mmol L1 free folate.  
 
cells at the same time after the addition of FR-targeted bo-
ron-10 containing nanoparticles (Figure 4B). However, the 
boron concentration in NFPAs was lower than in HeLa cells, 
indicating that the uptake ability of FR-targeted boron-10 
containing carbon nanoparticles in HeLa cells was more 
efficient than for NFPAs.  
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Figure 3  Cytotoxicity of FR-targeted boron-10 containing carbon nanoparticles of PA cell proliferation. NFPA cells expressing FR or non-FR-       
expressing GH adenoma cells (A) and positive control (HeLa) and negative control (T3-1 cells) (B) were incubated with various doses of FR-targeted bo-
ron-10 containing carbon nanoparticles for 24 h. The inhibitory rate of the treatment group was expressed as the % of control values. Data represent the 
mean±SD of triplicate experiments. ***, P<0.001 compared with control. 
 
Figure 4  Time course of boron accumulation in tumor cells. NFPA cells expressing FR or non-FR-expressing GH adenoma cells (A) and positive con-
trol (HeLa) and negative control (T3-1 cells) (B) were incubated with 0.1 g mL1 of FR-targeted boron-10 containing carbon nanoparticles for 2, 4, 8, 16 
and 24 h. Boron concentrations in tumors cells were evaluated by ICP-AES. Data represent the mean±SD of triplicate experiments. ***, P<0.001. 
2.5  The neutron capture therapeutic (NCT) effects of 
FR-targeted boron-10 containing carbon nanoparticles 
on cell viability of NFPAs  
To examine whether FR-targeted boron-10 containing car-
bon nanoparticles have neutron capture therapeutic (NCT) 
effects on NFPAs, in vitro cellular experiments were con-
ducted. The cell viability of NFPAs was decreased in a 
dose- and time-dependent manner after irradiation at a 
thermal neutron flux of 1.8×109 n cm s1. However, cells 
fed with the same dose of carbon nanoparticles without 
neutron irradiation or received same neuron irradiation 
without incubation with FR-targeted boron-10 containing 
carbon nanoparticles did not show a significant decrease in 
cell viability (Figure 5A). The similar results also were ob-
served in the Hela (Figure 5B).  
2.6  The neutron capture therapeutic (NCT) effects of 
FR-targeted boron-10 containing carbon nanoparticles 
on apoptosis of NFPAs cells  
To determine the effect of BNCT on apoptosis of NFPA 
cells, we performed an Annexin V-FITC apoptosis assay. 
Incubation with FR-targeted boron-10 containing carbon 
nanoparticles or neutron irradiation alone did not induce 
significant NFPA cell apoptosis compared with controls 
(without incubation with FR-targeted boron-10 containing 
carbon nanoparticles or neutron irradiation) (Figure 6A). 
Strikingly, the neutron irradiation induced apoptosis of 
NFPA cells incubated with FR-targeted boron-10 containing 
carbon nanoparticles increased by up to 28.6% (Figure 6B). 
Similar results were obtained in HeLa cells (Figure 6C and 
D). Taken together, FR-mediated BNCT significantly in-
duced apoptosis of NFPAs cells.  
2.7  The effect of BNCT on Bcl-2 and Bax expression 
To explore the molecular mechanisms of BNCT-induced 
apoptosis in NFPAs, the levels of Bcl-2, an inner mitochon-
drial membrane protein that inhibits apoptosis, and Bcl-2-      
associated X (Bax), a protein that promotes apoptosis by 
competing with Bcl-2 [19], were evaluated by Western blot. 
Irradiation with thermal neutrons did not alter the expres-
sion of Bcl-2 or Bax in NFPAs in the absence of incubation  
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Figure 5  Neutron capture therapeutic (NCT) effects of FR-targeted boron-10 containing carbon nanoparticles on tumors cell viability. After 24 h incuba-
tion with or without 0.1 mg mL1 of FR-targeted boron-10 containing carbon nanoparticles, NFPA cells expressing FR or non-FR-expressing GH adeno-
ma cells (A) and positive control (HeLa) and negative control (T3-1 cells) (B) were irradiated with a thermal neutron flux of 1.8×109 n cm2 s1. Then, cell 
viabilities were measured at 24 and 48 h after neutron irradiation. The cells in control group were not incubated with FR-targeted boron-10 containing carbon 
nanoparticles or irradiated with thermal neuron. (n.s., non significant; ***, P<0.001 compared with control. 
with FR-targeted boron-10 containing carbon nanoparticles 
(Figure 7A). However, after treatment with BNCT, the ex-
pression of Bcl-2 was markedly down-regulated, while Bax 
expression was simultaneously up-regulated. Densitometric 
analysis revealed a marked increase in the Bax/Bcl-2 ex-
pression ratio following treatment of BNCT, compared to 
controls and treatment with thermal neutron irradiation only 
(P<0.01) (Figure 7B). Taken together, these results indicate 
that the mechanisms of BNCT-induced apoptosis may partly 
involve the regulation of Bcl-2 and Bax expression. 
3  Discussion 
In the present study, we demonstrated that FR-targeted bo-
ron-10 containing carbon nanoparticles were selectively 
taken up by primary cultures of NFPAs via FR-mediated 
endocytosis. Furthermore, FR-mediated BNCT significantly 
decreased cell viability and increased apoptosis of NFPA 
cells.  
The study of BNCT has progressed in a variety of ma-
lignancies over recent decades [7]. In the clinic, BNCT is 
used to treat patients with high-grade gliomas, melanomas, 
liver metastasis of colon adenocarcinomas, malignant mel-
anomas, recurrent tumors of head and neck cancer, multiple 
liver tumors and oral cancer [20–25]. To the best of our 
knowledge, the effect of BNCT on PAs has not been tested 
yet, probably because PAs are benign tumors and general 
boron compounds have relatively low biologically weighted 
concentrations in PA tumor cells. However, aggressive PAs 
are frequently invasive of the surrounding anatomical 
structures and exhibit rapid growth. They are notoriously 
difficult to manage, are associated with a poor prognosis 
and are generally refractory to standard therapy. Therefore, 
the therapeutic options are limited [26]. For these reasons, 
we focused on the promising therapeutic effects of BNCT 
for aggressive pituitary tumors. Strikingly, in the present 
study, the FR-targeted boron-10 containing carbon nanopar-
ticles could selectively transport boron-10 to FR-expressing 
NFPAs but not FPAs, which fulfilled the basic requirements 
for BNCT. The BNCT experiments in this study further 
demonstrated that FR-mediated BNCT is an effective  
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Figure 6  Neutron capture therapeutic (NCT) effects of FR-targeted boron-10 containing carbon nanoparticles on apoptosis of tumors cells. Annexin 
V-FITC apoptosis assay was performed to detected cell apoptosis of NFPA cells (A and B) and HeLa cells (C and D) at 48 h after neutron irradiation. Data 
represent the mean±SD of triplicate experiments. ***, P<0.001 compared with control. 
therapeutic treatment for NFPAs without causing excessive 
radiation damage to the non-FR-expressing GH secreting 
adenomas, which is regarded as normal tissue. Taken to-
gether, our data showed that FR-mediated BNCT specifi-
cally killed primary culture FR-expressing NFPAs.  
One of the major challenges in BNCT is the development 
of ideal boron compounds that are selectively taken up by 
tumor cells. One previous study demonstrated that 
FR-targeted boron-10 containing carbon nanoparticles were 
specifically taken up by HeLa cells, an FR expressing cell 
line [14]. Other previous studies have also reported that 
FR was uniquely overexpressed in NFPAs but was not 
expressed by FPAs or normal pituitary glands cells [15,27]. 
It is worthwhile to determine whether a FR-targeted boron 
agent could be used in BNCT for NFPAs, especially inva-
sive NFPAs that are refractory to standard therapy. In the 
present study, we demonstrated that FR-targeted boron-10 
containing carbon nanoparticles could be taken up by 
FR-positive NFPAs more efficiently than non-FR ex-
pressing FPAs. Furthermore, the FR-mediated uptake of 
carbon nanoparticles could be inhibited by folic acid, sug-
gesting FR-mediated internalization may be involved in the 
selective delivery of boron-10 containing carbon nanoparti-
cles to NFPAs.  
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Figure 7  The expression of Bcl-2 and Bax proteins in NFPA cells after 
neutron irradiation. A, To evaluate the effect of FR-mediated BNCT on 
apoptosis-related proteins, Western blot analysis of Bcl-2 and Bax expres-
sion was performed 48 h after neutron irradiation. The representative blots 
of three independent experiments are shown. -actin was used as a loading 
control. B, Densitometric analysis of Bax/Bcl-2 expression ratio of the 
Western blots. The data are expressed as the mean±SD from three inde-
pendent experiments which were analyzed using one-way ANOVA. ***, 
P<0.001 compared with control. 
Our results are consistent with previous reports showing 
that FR-targeted boron compounds could be selectively 
taken up by FR-expressing tumor cells [28–31]. In the pre-
sent study, carbon nanoparticles were surface modified with 
folate moieties, and therefore could target FR-expressing 
NFPA cells via a FR-mediated endocytosis process. The 
folate moieties could generate green fluorescence under the 
FITC filter, and internalization of carbon nanoparticles 
could be determined by confocal laser scanning microscopy. 
The results in this study demonstrate that carbon nanoparti-
cles enter the cytoplasm of FR-expressing NFPA cells but 
not non-FPA expressing cells, indicating that FR-targeted 
carbon nanoparticles are an ideal delivery agent of boron for 
BNCT. Furthermore, we determined the concentration of 
boron in NFPA cells by ICP-AES was up to 246 g g1 24 h 
after incubation with the FR-targeted boron agent. This was 
approximately 15-fold higher than for GH-secreting ade-
noma cells. The boron concentration was higher than the 
standard therapeutic dose of 20–30 g g1 after 8 h incuba-
tion with FR-targeted carbon nanoparticles. The results 
demonstrated that FR-mediated boron-10 containing carbon 
nanoparticles are probably more efficacious for NFPA than 
first generation and second generation boron delivery agents 
(such as BPA and BSH) owing to its high selectivity and 
low toxicity to normal cells.     
More importantly, the cell viability of NFPAs adminis-
tered FR-targeted boron-10 containing carbon nanoparticles 
decreased and apoptotic cells increased after irradiation 
with the thermal neutron beam. BNCT may induce glioma 
cell apoptosis via activation of Bax and downregulation of 
Bcl-2 [32]. Consistent with a previous study, we observed 
that neutron irradiation induced the apoptosis of NFPA cells 
incubated with carbon nanoparticles up to 28.6%, compared 
to controls (2.1%, without incubation of carbon nanoparti-
cles or neutron irradiation). Treatment with neutron irradia-
tion alone or incubation with carbon nanoparticles alone did 
not induce apoptosis of NFPAs, indicating that apoptosis in 
NFPAs was induced by nuclear reactions occurring in bo-
ron-10 irradiated with thermal neutrons. Apoptosis, an ac-
tive process of cellular self-destruction, plays an important 
role in radiation-induced cell death [33]. Bcl-2 is an integral 
mitochondrial membrane protein that can prevent the initia-
tion of the cell apoptotic program [34]. Bax is an apopto-
sis-inducing protein that participates in cell death, which is 
counterbalanced by Bcl-2 [35]. The interactions of Bcl-2 
and Bax regulate apoptosis in cells [36]. When apopto-
sis-inducing protein Bax is present in excess, cells execute a 
death command; however, when anti-apoptosis protein 
Bcl-2 dominates, the program is blocked and cells survive 
[37]. Consistent with the increase in apoptotic cell death, 
FR-mediated BNCT increased the ratio of Bax/Bcl-2 in 
NFPA cells after 48 h of thermal neutron irradiation. Taken 
together, FR-mediated BNCT may induce apoptosis in 
NFPAs via regulating Bax/Bcl-2 expression.     
Although NFPAs were effectively suppressed by FR-    
mediated BNCT in vitro, no in vivo study was performed 
due to the scarcity of animal models of NFPA. It remains to 
be investigated whether the development of a useful animal 
model truly representing human NFPA is possible and to 
evaluate the effect of FR-mediated BNCT in this system.  
In conclusion, we present evidence that FR-targeted bo-
ron-10 containing carbon nanoparticles may be an ideal 
delivery agent of boron to NFPAs for BNCT. FR-mediated 
BNCT could decrease cell viability and significantly in-
crease apoptosis in NFPAs in vitro. Furthermore, our study 
also provides a novel insight into therapeutic strategies for 
invasive NFPA refractory to conventional therapy, while 
exploring these new applications of BNCT on tumors, espe-
cially benign tumors.  
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